

# Pieter J Eichhorn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/402421/publications.pdf>

Version: 2024-02-01

20  
papers

3,052  
citations

430874

18  
h-index

677142

22  
g-index

22  
all docs

22  
docs citations

22  
times ranked

7693  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. <i>Cancers</i> , 2021, 13, 1538.	3.7	37
2	Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma. <i>Cancers</i> , 2019, 11, 1176.	3.7	20
3	MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma. <i>Blood</i> , 2019, 134, 2046-2058.	1.4	25
4	c-Met activation leads to the establishment of a TGF $\beta$ <sup>2</sup> -receptor regulatory network in bladder cancer progression. <i>Nature Communications</i> , 2019, 10, 4349.	12.8	44
5	Ubiquitination and adaptive responses to BRAF inhibitors in Melanoma. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1497862.	0.7	9
6	Platforms for Investigating LncRNA Functions. <i>SLAS Technology</i> , 2018, 23, 493-506.	1.9	136
7	Deciphering the roles of lncRNAs in breast development and disease. <i>Oncotarget</i> , 2018, 9, 20179-20212.	1.8	42
8	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. <i>Journal of Experimental Medicine</i> , 2018, 215, 1913-1928.	8.5	41
9	USP26 regulates TGF $\beta$ <sup>2</sup> signaling by deubiquitinating and stabilizing SMAD7. <i>EMBO Reports</i> , 2017, 18, 797-808.	4.5	54
10	The roles of ubiquitin modifying enzymes in neoplastic disease. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2017, 1868, 456-483.	7.4	35
11	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. <i>Journal of Clinical Investigation</i> , 2013, 123, 2551-2563.	8.2	108
12	USP15 stabilizes TGF $\beta$ <sup>2</sup> receptor I and promotes oncogenesis through the activation of TGF $\beta$ <sup>2</sup> signaling in glioblastoma. <i>Nature Medicine</i> , 2012, 18, 429-435.	30.7	342
13	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. <i>Oncogene</i> , 2011, 30, 2547-2557.	5.9	471
14	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 <sup>+</sup> breast cancer patients. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 3761-3766.	7.1	291
15	NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. <i>Cancer Research</i> , 2008, 68, 8022-8030.	0.9	726
16	Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. <i>Cancer Research</i> , 2008, 68, 9221-9230.	0.9	474
17	A RNA Interference Screen Identifies the Protein Phosphatase 2A Subunit PR55 <sup>13</sup> as a Stress-Sensitive Inhibitor of c-SRC. <i>PLoS Genetics</i> , 2007, 3, e218.	3.5	40
18	PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 5397-5402.	7.1	40

#	ARTICLE	IF	CITATIONS
19	PR72, a novel regulator of Wnt signaling required for Naked cuticle function. <i>Genes and Development</i> , 2005, 19, 376-386.	5.9	67
20	A giant novel gene undergoing extensive alternative splicing is severed by a Cornelia de Lange-associated translocation breakpoint at 3q26.3. <i>Human Genetics</i> , 2004, 115, 139-48.	3.8	44